Optima Health Reports Strong FY25 Performance, Secures £210m MoD Contract and Expands via Acquisitions

A Year of Strategic Checkmates and Healthy Growth

Optima Health’s latest trading update reads like a playbook for how to execute a growth strategy with surgical precision. Let’s dissect why this AIM-listed occupational health specialist has analysts nodding approvingly into their Earl Grey.

Financial Fitness Report

The numbers tell their own story:

• £105m revenue for FY25 – hitting market expectations like a clinical thermometer hitting 37°C
• 7% H2 growth vs H1 – acceleration as the year progressed
• Net debt of £2.2m (excluding leases) – barely a rounding error for a firm this size

But the real intrigue lies beyond the headline figures…

The £210m MoD Coup

Securing the Armed Forces medical assessment contract isn’t just about the eye-watering sum – it’s strategic artillery for long-term dominance. Partnering with Serco, Optima becomes the NHS’s new best friend through its DART tech implementation. The 7-10 year timeframe suggests this is less a contract, more a institutional handshake.

Acquisition Chess Moves

Optima’s M&A strategy resembles a grandmaster clearing the board:

The Irish Gambit: Cognate Health

• €9m price tag for 30 clinics and 35 physicians
• Foot in Ireland’s door with €7m revenue boost

Home Turf Consolidation: BHSF & Care first

• £1.4m for BHSF’s 60 clinicians and £7m revenue
• £15k (!) for Care first’s £3.7m EAP business

That last acquisition price isn’t a typo – it’s the corporate equivalent of finding a Monet at a car boot sale.

The Road Ahead

With preliminary results due in July, watch for:

• EBITDA accretion timelines from acquisitions
• DART’s NHS adoption metrics
• International expansion whispers

CEO Jonathan Thomas’s closing remark says it all: “We continue to lead the transformation of workplace health” – corporate speak translating to “We’re just getting started.”

For investors, Optima presents a compelling cocktail – NHS-approved moat, military-grade contracts, and M&A nous. The only prescription? Keep this one on your watchlist.